NEW YORK (GenomeWeb) – CareDx announced after the close of the market on Thursday that it has sold approximately 592,000 units in a private placement for aggregate proceeds of about $22.1 million, $8 million of which will be reserved for future investment by certain shareholders.

The units — which each consist of one share of common stock, five shares of mandatorily convertible preferred stock, and warrants to purchase three shares of common stock — were sold to selected institutional and accredited investors, including new and current shareholders. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.